Work

Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2015-ct234

Authors: Patricia LoRusso, Ian Krop, Kathy Miller, Cynthia Ma, Barry A. Siegel, Anthony F. Shields, Istvan Molnar, Thomas Wickham, Joseph Reynolds, Karen Campbell, Bart Hendriks, Ty McClure, Victor Moyo, Pamela Munster

Institutions: Yale University, Dana-Farber Cancer Institute, Indiana University Indianapolis, Washington University in St. Louis, Merrimack Pharmaceuticals (United States), University of California, San Francisco

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2306345333

Cites:

Cited by: 30

Related to: 10